Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07200180

Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery

Currently, over 400,000 reconstructive surgeries on carotid arteries are performed annually worldwide, including carotid endarterectomy (CEA) and carotid stenting. These interventions have proven effective in preventing ischemic stroke in patients with hemodynamically significant carotid artery stenoses. However, even following a technically successful procedure, the risk of perioperative ischemic brain injury persists. According to meta-analyses, one in five patients exhibits covert ("silent") strokes after reconstructive interventions, with their frequency being ten times higher than that of clinically manifest events. Such lesions are associated with cognitive decline and an increased risk of dementia. An additional risk factor is the "no-reflow" phenomenon-an impairment of microcirculatory reperfusion that occurs even after the restoration of macrovascular blood flow, thereby limiting the effectiveness of surgical revascularization.

Cognitive disorders and postoperative delirium, observed in 15-30% of patients after CEA, adversely affect rehabilitation and long-term prognosis. To date, there are no reliable pharmacological strategies to prevent these complications.

In this context, inert gases have attracted significant interest as potential neuroprotective agents. Xenon, despite its proven efficacy, is limited by high cost and challenges in industrial production. Argon, in contrast, is accessible, safe, and technologically straightforward to administer. In preclinical models of stroke and ischemia-reperfusion, argon has demonstrated pronounced anti-apoptotic, anti-inflammatory, and antioxidant effects, mediated through the regulation of TLR2/4-, ERK1/2-, Nrf2-, and NF-κB-dependent signaling pathways. Its ability to suppress microglial activation towards the M1 phenotype and inhibit the NLRP3 inflammasome has been noted, which reduces neuroinflammation and decreases the volume of secondary neuronal damage. Short-term argon inhalation in healthy volunteers has shown a favorable safety profile with no adverse effects on cerebral hemodynamics.

Thus, it is highly relevant to clinically test the hypothesis that perioperative inhalation of an argon-containing gas mixture can reduce the incidence of ischemic brain injuries and cognitive impairments in patients undergoing CEA.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age > 18 years
  • elective carotid artery surgery
  • general anesthesia
  • written informed consent

Exclusion criteria

  • The presence of any mental disorder according to the International Classification of Diseases 10th Revision which is confirmed by a psychiatrist.
  • The presence of any neuromuscular disease according to the International Classification of Diseases 10th Revision
  • Heart failure equal 3 or 4 class according to the New York Heart Association Functional Classification
  • Pregnant or breast-feeding women
  • Inability to undergo a preoperative assessment for any reason
  • Previously enrolled in this trial

Treatment and study plan

Аrgon-oxygen breathing mixture

Drug

Patients receive a course of inhalations with an argon-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day

Nitrogen-oxygen breathing mixture

Drug

Patients receive a course of inhalations with an nitrogen-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day

Primary outcomes

  1. Incidence of postoperative delirium

    Time frame: 30 days

    Number of patients with even one positive confusion assessment method for the intensive care unit or 3-minute confusion assessment method

Secondary outcomes

  1. Incidence of emergence delirium

    Time frame: 30 days

    Number of patients with positive the confusion assessment method for the intensive care unit as soon as they reach Aldrete score of 9 points

  2. Incidence of postoperative agitation

    Time frame: 30 days

    Richmond agitation-sedation scale more or equal +2 evaluated from the end of volatile anesthetic supply to the moment when a patient reaches Aldrete score of 9 points Richmond agitation-sedation scale: minimum value = -5 (Unarousable - no response to voice or physical stimulation) maximum value = +4 (Combative - overtly combative or violent; immediate danger to staff) Adequate patients have the results of Richmond agitation-sedation score equal 0 (Alert and calm; Spontaneously pays attention to caregiver)

  3. Duration of postoperative delirium

    Time frame: until 1 month after surgery

    30 days - number of days in which patient had positive confusion assessment method for the intensive care unit or 3-minute confusion assessment method

  4. Incidence of cognitive dysfunction

    Time frame: 30 days

    reduction of ≥1 standard deviation in the Montreal Cognitive Assessment (MoCA) total z-score compared to the preoperative assessment

  5. Incidence of overt stroke

    Time frame: 30 days

    Number of overt strokes

  6. Incidence of covert stroke

    Time frame: 30 days

    Number of covert strokes

  7. Length of stay in the intensive care unit

    Time frame: 30 days

    Number of days in intensive care unit

  8. Length of hospitalization

    Time frame: 30 days

    Number of days in hospital

  9. Serum level of S100 beta protein

    Time frame: 2 days after surgery

    Serum level of S100 beta protein

  10. Serum level of neuron-specific enolase

    Time frame: 2 days after surgery

    Serum level of neuron-specific enolase

  11. Serum level of interleukin-6

    Time frame: 2 days after surgery

    Serum level of interleukin-6

Study contacts

Contact information is provided by the study sponsor or research team.

Oleg Grebenchikov, MD, PhD

CONTACT

[email protected]

+79686494147

Sponsors and collaborators

Lead sponsor

Negovsky Reanimatology Research Institute

Other Gov

Collaborators

  • GBWZ of Moscow city hospital n.a. S.P. Botkin

Registry information

Official study title

Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery (PAIRS Trial)

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 30, 2025
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.